Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk next-gen shot shows 22% weight loss in early results
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.
Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here.
The Score: Novo Nordisk, Oracle, Netflix, and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week’s news.
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo Nordisk has been able to report in more than a month.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,
Novo Nordisk Soars 12% With Ozempic Alternative
Novo Nordisk (NVO) experienced a significant surge in pre-market trading on Friday, with its stock climbing 12% following the announcement of promising results from an early-stage clinical trial for its new obesity treatment,
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Investors who lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
STAT14h
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
Novo Nordisk Vaults Above LVMH as Europe's Biggest Company
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
STAT15h
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz
Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
These Stocks Are Moving the Most Today: Texas Instruments, Meta, Verizon, Boeing, Tesla, Amex, Novo Nordisk, and More
Texas Instruments falls after the chip maker’s first-quarter earnings forecast misses estimates, Boeing declines after ...